share_log

九典制药(300705.SZ):多款仿制药有望参加首轮国家集采,为公司未来利润增长提供支撑

hunan jiudian pharmaceutical (300705.SZ): Multiple generic drugs are expected to participate in the first round of national centralized procurement, providing support for the company's future profit growth.

Gelonghui Finance ·  Nov 7, 2024 23:24

On November 8th, Gelonhui reported that hunan jiudian pharmaceutical (300705.SZ) received a specific object's research on November 8, 2024, regarding the expected contribution of the anti-inflammatory and analgesic Babu plaster and products to be launched in the next two years on performance. The company stated that currently, the sales channels for anti-inflammatory and analgesic Babu plaster are mainly OTC. Looking ahead, it is expected that the Fluibuprofen gel patch and Indomethacin gel patch, set to be launched next year, will further enrich the company's external patch product line, enabling rapid penetration into hospitals and chain markets with existing sales resources and networks. In addition, several generic drugs are expected to participate in the first round of national centralized procurement, providing support for the company's future profit growth.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment